PHASQ Stock Crashes 99% on May 4, 2026 After Bankruptcy

PHASQ stock has become one of the market’s most severe casualties, trading at just $0.000001 USD on the PNK exchange as of May 4, 2026. The biotechnology company PhaseBio Pharmaceuticals, Inc. has experienced a devastating 99% decline from its previous close of $0.0001. This catastrophic collapse reflects the company’s ongoing struggles following its voluntary Chapter 11 bankruptcy filing in October 2022. The Malvern, Pennsylvania-based firm, which once focused on cardiovascular drug development, now trades in penny stock territory with minimal trading volume. Understanding PHASQ stock’s current position requires examining the company’s clinical pipeline, financial deterioration, and what bankruptcy reorganization means for shareholders.

PHASQ Stock Price Collapse and Trading Activity

PHASQ stock has reached penny stock status with virtually no recovery prospects. The stock trades at $0.000001, down from $0.0001 just one trading session ago, representing a staggering one-day loss. Trading volume sits at only 2,500 shares, far below the 22,310-share average volume, indicating minimal investor interest.

The year-to-date performance tells an even grimmer story. PHASQ stock has fallen 99.99% over the past year and 99.99997% over the past five years. The 52-week range shows the stock peaked at $0.0399 but has since collapsed to its current microscopic valuation. This represents one of the most severe equity destructions in the biotech sector.

PhaseBio Pharmaceuticals’ Bankruptcy and Pipeline Status

PhaseBio Pharmaceuticals filed for Chapter 11 reorganization on October 23, 2022, in the U.S. Bankruptcy Court for the District of Delaware. The company was developing three main drug candidates for cardiovascular diseases, including bentracimab (PB2452), a reversal agent for the antiplatelet drug ticagrelor in Phase III trials.

The company also pursued PB1046 for pulmonary arterial hypertension and PB6440 for resistant hypertension. However, bankruptcy proceedings have effectively halted clinical development. Track PHASQ on Meyka for real-time updates on any reorganization developments or asset sales that could affect shareholders.

Financial Metrics and Fundamental Deterioration

PHASQ stock’s financial metrics reveal a company in severe distress. The company reports negative earnings per share of -$2.14, with a market capitalization of essentially zero. Operating cash flow per share stands at -$1.08, while free cash flow per share is -$1.14, indicating ongoing cash burn.

The company’s balance sheet shows negative book value per share of -$2.12, meaning liabilities exceed assets. Net profit margin sits at a devastating -12.1%, and return on assets is -2.17%. These metrics confirm that PhaseBio is not generating revenue sufficient to cover operational costs or debt obligations.

Market Sentiment and Liquidation Outlook

Market sentiment around PHASQ stock is decidedly bearish, with the stock trading at penny stock levels that typically precede delisting or complete equity wipeout. The company’s enterprise value is negative at -$33.48 million, suggesting liabilities far exceed any recoverable asset value.

In bankruptcy reorganization, common shareholders typically face significant dilution or complete elimination. The current stock price reflects market expectations that equity holders will recover little to nothing. Any remaining value will likely flow to creditors and secured debt holders first, leaving common shareholders with minimal recovery prospects.

Final Thoughts

PHASQ stock represents a cautionary tale of biotech failure and financial collapse. Trading at $0.000001 on May 4, 2026, the stock has lost 99% of its value and faces an uncertain future under Chapter 11 reorganization. PhaseBio Pharmaceuticals’ clinical pipeline, once promising for cardiovascular treatments, has stalled amid bankruptcy proceedings. The company’s negative earnings, cash burn, and negative book value indicate minimal shareholder recovery prospects. Investors holding PHASQ stock should prepare for potential delisting and complete equity loss. This situation underscores the high-risk nature of penny stocks and early-stage biotech investments. Meyka AI’s analysis platform tra…

FAQs

Disclaimer:

Stock markets involve risks. This content is for informational purposes only. Past performance does not guarantee future results. Meyka AI PTY LTD provides market analysis and data insights, not financial advice. Always conduct your own research and consider consulting a licensed financial advisor.